BIOCODEX in the news

The Biocodex Microbiota Foundation is offering a ‣35,000 research grant to Canadian scientists for microbiota-related projects, with applications due by October 30, 2026.

The Biocodex Microbiota Foundation is inviting Canadian researchers to apply for its 2026 National Grant, offering 35,000 euros for projects focused on microbiota research.

Biocodex's Émilie Pertuiset discusses the new, effective today, reimbursement for reusable menstrual protection, emphasizing its public health significance and the role of pharmacists.

THX Pharma reported its first revenue of 3.2 M… in the first half of 2026, driven by a 173 M… licensing deal with Biocodex for Batten-1 and TX01, which includes a 12 M… upfront payment and shifts development costs to Biocodex.

THX Pharma generated its first revenue of –3.2 million in H1 2026, driven by a Biocodex agreement that also reconfigures its financing model for drug development.

THX Pharma recorded its initial revenue of –3.2 million in H1 2026 from the Biocodex agreement, while increasing operating expenses due to the Batten-1 Phase 3 trial, resulting in a reduced net loss and a strong cash balance.

Biocodex Vietnam received two HR Asia Awards in 2026, including Best Companies to Work for in Asia and a Diversity, Equity, and Inclusion Award.

Médunik Canada signed an exclusive promotional services agreement with Biocodex for Diacomit® in Canada, taking over all sales, marketing, and medical affairs for the Dravet syndrome treatment.

Médunik Canada signed an exclusive agreement with Biocodex for the sales, marketing, and medical affairs of Diacomit® in Canada, a treatment for Dravet syndrome.

Biocodex Microbiota Foundation announced its 2026 National Scholarship in Canada, offering a €35,000 grant for research into human microbiota, with applications due by October 30, 2026.

Médunik Canada secured an exclusive agreement with Biocodex for the Canadian promotion and distribution of Diacomit, a medication for Dravet syndrome.

THX Pharma, BBDF, and Biocodex submitted regulatory applications for a Phase 3 clinical trial of Batten-1, a miglustat formulation for juvenile Batten disease (CLN3), aiming to recruit patients by year-end pending approvals.

THX Pharma, BBDF, and Biocodex have submitted regulatory applications for the Phase 3 clinical trial of Batten-1, an oral miglustat formulation, for juvenile Batten disease (CLN3).

THX Pharma, BBDF, and Biocodex submitted regulatory requests for a Phase 3 clinical trial of Batten-1 to treat juvenile Batten disease, with Biocodex fully funding the study.

Biocodex Microbiota Foundation is offering a –35,000 research grant to Canadian scientists for projects on microbiota in human health and disease.

Biocodex SAS's employee count is projected to increase to 1,440 by 2026, a 14.1% growth from 2023.

Awareness of microbiota is growing, but public understanding and patient education by healthcare professionals are lagging.

The Biocodex Microbiota Foundation is inviting Canadian researchers to apply for a ‰35,000 grant to advance microbiota research in human health and disease.

Biocodex Microbiota Foundation is offering a 35,000 euro grant to Canadian researchers for microbiota-focused projects in human health and diseases.